Nexgel, Inc · NASDAQ:NXGL
Nexgel — Investor Presentation (July 2024)
24 slides from Nexgel's investor presentation, Jul 29, 2024
Slide 1: NEXGEL Investor Presentation July 2024
@NEXCEL @ NEXGEL advanced hydrogel solutions Investor Presentatio July 2024 IX | / \ NASDAQ: NXGL \ | \ My
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains certain forward-looking statements, including those relating to the Company's product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and
Slide 3: NEXGEL - Who We Are and What We Do
NEXGEL - Who We Are and What We Do After two decades of creating custom hydrogel solutions for large medical device companies, our business today includes the development of patented medical devices, custom/white label products, and OTC healthcare consumer products. Additionally, we have invested in
Slide 4: Competitive Advantage of State-of-the-Art Manufacturing Facilities in NA
Competitive Advantage: 1 of 2 State-of-the-Art Manufacturing Facilities in NA Medical grade technology and facility, providing gels to multi-national device companies for over 20 years with sufficient capacity to fulfill consumer and healthcare segments >1.4 Billion square inches 1 of 2 manufacturin
Slide 5: Hydrogels for Consumer and Medical Applications
Hydrogels for Consumer and Medical Applications * Electron beam technology eliminates the need for harmful chemicals in cross-linking, which, along with our paraben-free formulation, makes our patches the only option for many medical device applications and preferred among consumers * Gentle formula
Slide 6: Multiple Shots on Goal
Multiple Shots on Goal Custom & White Label NEXGEL is Bringing proven addressing the medical-grade importance of technology to skin integrity OTC and Beauty and overall & Cosmetics for skincare with a the first time medical device through many licensing model new consumer products & applications @NE
Slide 7: Multiple Aspirational Medical Device Opportunities
Multiple Aspirational Medical Device Opportunities Addressing the importance of skin integrity and overall skincare with a medical device @NEXCEL NASDAQ: NXGL \
Slide 8: Select Medical Device Applications Examples
Select Medical Device Applications Examples Drug Delivery - Potential for drug delivery through unique hydrogels Leading Brand NEXDrape - Askin friendly” solution for the surgical drape 510(k) market * Disrupting the rapidly growing surgical drape industry by providing consistent adhesion; greater s
Slide 9: Consumer Health & Beauty
Consumer Health & Beauty Bringing proven medical-grade technology to OTC and B&C for the first time through many new consumer products & applications
Slide 10: Multiple Low-Risk Revenue Paths
Multiple Low-Risk Revenue Paths Leveraging Hydrogel Technology your ‘ 4 Custom & shin friendly White Label — PATCH CO.— NOW PARABEN-FREE NASDAQ: NXGL. DTC/ E-Commerce Proprietary Brands 10
Slide 11: Custom & White Label
Custom & White Label NEXGEL supplies OTC brands with unique gentle hydrogel-based products through a custom and white label offering - All UV cured hydrogel patches contain AMP-acrylates/vinyl Isodecanoate crosspolymer, Toluene, and Vinyl acetate, or similar chemicals, which are non-starters for the
Slide 12: Joint Venture with C.G. Laboratories
Joint Venture with C.G. Laboratories 50-50 ownership in converting and packaging business in Granbury, Texas * CG Labs current converting and packaging division is one of NEXGEL’s largest customers for many years, revenue generating and already profitable + Transaction immediately increases converti
Slide 13: AbbVie
AbbVie (NYSE: ABBV) CG Converting and Packaging Is the exclusive supplier of gel pads to be used with AbbVie's Rapid Acoustic Pulse device for the improvement in the appearance of cellulite + Allergan Aesthetics, acquired by AbbVie, purchased Soliton, the owner of the Resonic technology, for $550 mi
Slide 14: STADA Arzneimittel AG
STADA Arzneimittel AG Partnership with European leader in consumer health supports expansion of NEXGEL OTC product portfolio + In 2022, STADA generated revenue of EUR 3.8 billion and EBITDA of EUR 885 million. + STADA already focuses on consumer healthcare products, generics and specialty pharm, sel
Slide 15: Cintas Corporation
Cintas Corporation Cintas is a leading provider of corporate identify uniforms, first aid and safety products and services to over 7 million businesses across North Anerica * Cintas will distribute SilverSeal, NEXGEL’s hospital-grade dressing for wounds and burns to its customers in many sectors inc
Slide 16: NEXGEL Branded Products
NEXGEL Branded Products ahd PATCH CO,— SilverSeal NASDAQ: NXGL. 16
Slide 17: SilverSeal Anti-Microbial Data
SilverSeal® Anti-Microbial Data * SilverSeal® study in SAGE Journals’ Scars, Burns and Healing publication: Demonstrated statistically significant improvement of skin functionality, fewer negative symptoms, and a reduction of scar appearance relative to standard petroleum-based dressing. * Validatio
Slide 18: SilverSeal Opportunity
SilverSeal® Opportunity 40 patient double-blinded study data will allow NEXGEL to make a scar reduction daim Data has been submitted for peer review and publication 12 Weeks - Treated 12 Weeks — With SilverSeal® Treated With Petroleum! + SilverSeal® currently being sold for OTC wound care online- sa
Slide 19: M&A Strategy: Consumer Brand Acquisition
M&A Strategy: Consumer Brand Acquisition Kenkoderm Skincare Line Silly George Beauty Brand + Acquisition completed in December 2023 + Acquisition completed in May 2024 + Complimentary line of alternative psoriasis treatments + Specialty eye and eyelash consumer product line + Profitable (ttm) and ex
Slide 20: Financial Overview
Financial Overview \ @NEXGEL NASDAQ; NXGL
Slide 21: Revenue Growth with Scalable Infrastructure
Revenue Growth with Scalable Infrastructure gas of march 31, 2024 Income Statement: + Q1 2024 Total revenue: $1.27 million, + ~104% YOY * Q1 2024 Contract manufacturing: $601K in revenue, +58% YOY + Q1 2024 Branded Product: $617K in revenue, +178% YOY * Q1 2024 Gross profit margin was 21.9% as compa
Slide 22: Revenue Growth / Guidance for 2024
Revenue Growth / Guidance for 2024 $3,000 $2,500 $2,000 $1,500 $1,000 $500 INS $1.17M, — $1.22M, 108% yoy +115% YoY 922023 32023 $2.6M +140% YOY $22M 483% YOY Siam si.27m— *20%YOY 100% YOY $L0sM, +110% Yor 42023 Qt 2024 22024" 03 20246 a4 20246" NASDAQ: NXGL. * Preliminary record second quarter 2024
Slide 23: Multiple Paths for Growth
Multiple Paths for Growth Scalable platform with multiple shots on goal and path to cash flow positive by end of 2024 Medical Device Custom & White Label Branded Products Aspirational, low-cost medical device opportunities in multi-billion hospital market. Licensing model that will evolve in 2025. S
Slide 24: Contact Us
Contact Us Investor Relations: KCSA Strategic Communications Valter Pinto, Managing Director PH: (212) 896-1254 NEXGEL@KCSA.com \j N | NASDAQ; NXGL \ IN /| if